Preferred Label : Oxbryta;
Origin ID : M000736658;
Related record
- See also inter- (CISMeF)
https://www.has-sante.fr/jcms/p_3361556/fr/oxbryta-voxelotor-anemie-hemolytique-severe
2022
false
false
false
France
insurance, health, reimbursement
treatment outcome
voxelotor
administration, oral
hematologic agents
adult
adolescent
drug therapy, combination
hydroxyurea
evaluation of the transparency committee
Oxbryta
voxelotor
anemia, sickle cell
---
Suspended - This medicine is currently suspended from use in the European Union
https://www.ema.europa.eu/en/medicines/human/EPAR/oxbryta
2022
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
voxelotor
voxelotor
voxelotor
orphan drug production
anemia, sickle cell
Oxbryta
drug approval
europe
adolescent
adult
administration, oral
aged
hematologic agents
hematologic agents
product surveillance, postmarketing
pregnancy
breast feeding
drug therapy, combination
drug interactions
hemoglobin, sickle
drug evaluation, preclinical
---
